^
    Back
    Association details:
    Biomarker:CLDN18.2 expression
    Cancer:Gastric Cancer
    Drug:givastomig (TJ-CD4B) (CLDN18.2 inhibitor, CD137 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    SITC 2023
    Title:

    792 Givastomig, a novel Claudin18.2/4–1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer

    Published date:
    11/04/2023
    Excerpt:
    Givastomig elicited tumor-killing activity against CLDN18.2-positive MKN-45#14 and MKN-45#18 cells but not CLDN18.2-negative MKN-45 cells. Interestingly, bystander tumor-killing was observed in a mixture of MKN-45#14 cells and MKN-45 cells at various ratios in the presence of givastomig.
    DOI:
    10.1136/jitc-2023-SITC2023.0792
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Immunother Cancer
    Title:

    CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation

    Published date:
    06/26/2023
    Excerpt:
    Furthermore, in humanized 4-1BB transgenic mice inoculated with human CLDN18.2-expressing tumor cells, givastomig/ABL111 induced a localized immune activation in tumor as evident by the increased ratio of CD8+/regulatory T cell, leading to the superior antitumor activity and long-lasting memory response against tumor rechallenge.
    DOI:
    10.1136/jitc-2023-006704